• Explore /
  • Poster
  • / PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible <em>FGFR3 </em>alterations.

PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations.

Abstract Poster

Authors

Siamak Daneshmand

Siamak Daneshmand

Keck School of Medicine of USC, Los Angeles, CA

Siamak Daneshmand , Petros Grivas , Srikala S. Sridhar , Shilpa Gupta , Joaquim Bellmunt , Guru Sonpavde , Mark T. Fleming , Seth P. Lerner , Yohann Loriot , Hao Wang , Hiywot Takkele , Corina Andresen , Jessica Rearden , Craig Berman , Sumanta K. Pal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT04197986

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS5095)

DOI

10.1200/JCO.2020.38.15_suppl.TPS5095

Abstract #

TPS5095

Poster Bd #

164

Abstract Disclosures

Similar Posters

First Author: Sumanta K. Pal

First Author: Suzanne Cole

First Author: Petros Grivas

First Author: Yuming Zhu